Register or Sign in to Save this opportunity, or Send an Inquiry.
S100A9: A New Target for the Development of Drugs Addressing Chronic Inflammation
AmorChem Canada flag Canada
Abstract ID:
The anti-S100A9 monoclonal antibody is directed against a novel target covering chronic inflammation and autoimmune diseases.
Send an Inquiry
RE:
Participants
You

The technology is based on a novel target, the S100A9 protein which plays a critical role in turning acute inflammation into a chronic state. The S100A9 protein acts as an amplifier of leukocyte migration during inflammation. It is also a potent inducer of pro-inflammatory cytokine production like TNFα, IL-1β, and IL-6. As such, S100A9 represents a very promising new therapeutic target for the control of inflammation. Anti-S100A9 antibodies have been developed and have been shown to be as efficacious as anti-TNF in mouse models of Crohn's disease and rheumatoid arthritis.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
Out-licensing or collaboration
FEATURED
Last Updated Jul 2017
Technology Type THERAPEUTIC
Phase of Development PRECLINICAL
CORPORATION

Opportunity Contact


Warning: include(js_message_scripts_n2.php) [function.include]: failed to open stream: No such file or directory in /home/pharmalicensing/public_html/detail.php on line 833

Warning: include() [function.include]: Failed opening 'js_message_scripts_n2.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/pharmalicensing/public_html/detail.php on line 833